NASDAQ:CGEM Cullinan Oncology (CGEM) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free CGEM Stock Alerts $17.88 +0.56 (+3.23%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$17.61▼$19.9750-Day Range$15.32▼$19.0252-Week Range$7.64▼$20.62Volume1.26 million shsAverage Volume456,405 shsMarket Capitalization$770.02 millionP/E RatioN/ADividend YieldN/APrice Target$27.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cullinan Oncology alerts: Email Address Cullinan Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside55.2% Upside$27.75 Price TargetShort InterestBearish5.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 25 Articles This WeekInsider TradingSelling Shares$1.44 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.55) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector521st out of 913 stocksBiological Products, Except Diagnostic Industry73rd out of 134 stocks 3.5 Analyst's Opinion Consensus RatingCullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCullinan Oncology has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.49% of the float of Cullinan Oncology has been sold short.Short Interest Ratio / Days to CoverCullinan Oncology has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cullinan Oncology has recently increased by 53.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Oncology does not currently pay a dividend.Dividend GrowthCullinan Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 3.0 News and Social Media Coverage News SentimentCullinan Oncology has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Cullinan Oncology this week, compared to 1 article on an average week.Search Interest7 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows4 people have added Cullinan Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,624.00 in company stock.Percentage Held by InsidersOnly 8.82% of the stock of Cullinan Oncology is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cullinan Oncology are expected to grow in the coming year, from ($3.55) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Oncology is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Oncology is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Oncology has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Cullinan Oncology Stock (NASDAQ:CGEM)Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesApril 18, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Cullinan Oncology, Inc.'s Q1 2024 Earnings (NASDAQ:CGEM)April 17, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 18, 2024 | Paradigm Press (Ad)Could Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 17, 2024 | americanbankingnews.comCullinan Oncology (NASDAQ:CGEM) Price Target Cut to $29.00 by Analysts at HC WainwrightApril 16, 2024 | markets.businessinsider.comBuy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 TherapyApril 16, 2024 | bizjournals.comCullinan rebrands with $280M private offering, pivot away from cancerApril 16, 2024 | finance.yahoo.comCullinan changes name, pivots to autoimmune diseaseApril 16, 2024 | markets.businessinsider.comCullinan To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-MarketApril 18, 2024 | Paradigm Press (Ad)Could Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 16, 2024 | markets.businessinsider.comCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via EquityApril 16, 2024 | marketwatch.comCullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private PlacementApril 16, 2024 | msn.comWilliam Blair Initiates Coverage of Cullinan Oncology (CGEM) with Outperform RecommendationApril 16, 2024 | globenewswire.comCullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 16, 2024 | globenewswire.comCullinan Therapeutics Announces Oversubscribed $280 million Private PlacementApril 16, 2024 | americanbankingnews.comCullinan Oncology (NASDAQ:CGEM) Receives New Coverage from Analysts at William BlairApril 13, 2024 | americanbankingnews.comCullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $17.06March 16, 2024 | finance.yahoo.comCullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn SituationMarch 14, 2024 | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023March 14, 2024 | finanznachrichten.deCullinan Oncology, Inc.: Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 14, 2024 | benzinga.comCullinan Oncology: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comCullinan Oncology Announces FDA Clearance Of IND Application For CLN-619March 1, 2024 | globenewswire.comCullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaFebruary 27, 2024 | globenewswire.comCullinan Oncology to Participate in Upcoming Investor ConferencesFebruary 12, 2024 | investing.comCullinan Oncology LLC (CGEM)January 31, 2024 | finance.yahoo.comChief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology IncSee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/17/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees85Year FoundedN/APrice Target and Rating Average Stock Price Target$27.75 High Stock Price Target$30.00 Low Stock Price Target$22.00 Potential Upside/Downside+55.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.11% Return on Assets-30.39% Debt Debt-to-Equity RatioN/A Current Ratio17.07 Quick Ratio17.07 Sales & Book Value Annual Sales$18.94 million Price / Sales40.66 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book1.69Miscellaneous Outstanding Shares43,066,000Free Float39,268,000Market Cap$770.02 million OptionableOptionable Beta0.33 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Comp: $1.16MDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Comp: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kDr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsCabaletta BioNASDAQ:CABACARGO TherapeuticsNASDAQ:CRGXHilleVaxNASDAQ:HLVXREGENXBIONASDAQ:RGNXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 82,910 shares on 3/11/2024Ownership: 4.141%Goldman Sachs Group Inc.Bought 42,204 shares on 3/1/2024Ownership: 0.300%American International Group Inc.Bought 972 shares on 2/28/2024Ownership: 2.891%Price T Rowe Associates Inc. MDBought 7,620 shares on 2/16/2024Ownership: 0.051%GSA Capital Partners LLPBought 10,246 shares on 2/16/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CGEM Stock Analysis - Frequently Asked Questions Should I buy or sell Cullinan Oncology stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Oncology's stock price target for 2024? 6 Wall Street analysts have issued 1 year price objectives for Cullinan Oncology's stock. Their CGEM share price targets range from $22.00 to $30.00. On average, they expect the company's share price to reach $27.75 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2024? Cullinan Oncology's stock was trading at $10.19 at the beginning of the year. Since then, CGEM stock has increased by 75.5% and is now trading at $17.88. View the best growth stocks for 2024 here. Are investors shorting Cullinan Oncology? Cullinan Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,440,000 shares, an increase of 53.9% from the March 15th total of 935,400 shares. Based on an average daily trading volume, of 423,600 shares, the short-interest ratio is presently 3.4 days. Approximately 5.5% of the shares of the company are short sold. View Cullinan Oncology's Short Interest. When is Cullinan Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CGEM earnings forecast. How were Cullinan Oncology's earnings last quarter? Cullinan Oncology, Inc. (NASDAQ:CGEM) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.42. What ETF holds Cullinan Oncology's stock? Virtus LifeSci Biotech Clinical Trials ETF holds 10,181 shares of CGEM stock, representing 1.59% of its portfolio. When did Cullinan Oncology IPO? Cullinan Oncology (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. How do I buy shares of Cullinan Oncology? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEM) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsBiden out June 13; Kamala won’t replace him?Paradigm PressTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsUrgent alert: open this for a huge profit potentialTimothy SykesOptions trading has suddenly become more reliable.Eagle PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.